Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Amortization of Deferred Charges: 2019-2024

Historic Amortization of Deferred Charges for ImmunityBio (IBRX) over the last 3 years, with Dec 2024 value amounting to $5.0 million.

  • ImmunityBio's Amortization of Deferred Charges fell 29.66% to $5.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $22.6 million, marking a year-over-year decrease of 46.72%. This contributed to the annual value of $22.6 million for FY2024, which is 46.72% down from last year.
  • ImmunityBio's Amortization of Deferred Charges amounted to $5.0 million in Q4 2024, which was down 19.23% from $6.2 million recorded in Q3 2024.
  • In the past 5 years, ImmunityBio's Amortization of Deferred Charges registered a high of $12.3 million during Q2 2023, and its lowest value of $370,000 during Q1 2022.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $6.0 million (2024), whereas its average is $6.8 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 3,017.84% in 2023, then crashed by 52.54% in 2024.
  • Quarterly analysis of 3 years shows ImmunityBio's Amortization of Deferred Charges stood at $7.8 million in 2022, then decreased by 8.20% to $7.1 million in 2023, then decreased by 29.66% to $5.0 million in 2024.
  • Its last three reported values are $5.0 million in Q4 2024, $6.2 million for Q3 2024, and $5.8 million during Q2 2024.